United States · Wires & real time · PR Newswire
Pentixapharm Announces Progress of Pivotal Phase 3 PANDA Study; Will Host Third Quarter Webcast on November 12, 2026
No FDA comments on the study protocol submitted in August 2026, including the primary endpoints and the planned number of approximately 325 patients; central U.S. ethics committee…
Read the full article on PR Newswire Sign in to saveMarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)
